Moderna, Inc.(MRNA) - Stock detail

Moderna, Inc.

US
MRNA
Moderna, Inc.(Listing date: 12/07/2018)

Moderna, Inc. was incorporated under Delaware law on July 22, 2016. The company is a leader in the field of messenger ribonucleic acid (mRNA) medicine. Through more than a decade of work at the intersection of science, technology, and health, the company has developed drugs with unprecedented speed and efficiency, including one of the earliest and most effective COVID-19 vaccines. The company's mRNA platform has enabled the development of therapies and vaccines for infectious diseases, immuno-oncology, rare diseases, and autoimmune diseases. With a unique culture and a global team driven by Moderna's values and mindset, the company strives to transform the future of human health in a responsible manner and to deliver the greatest possible impact to people through mRNA medicines.

AI Trading DecisionBuy
Generated at:2026-03-04 16:41:45
Analysis based on Moderna, Inc. financial data including Q3 2025 earnings showing 44.23% YoY revenue decline, current stock price of $57.80, technical indicators (moving averages, RSI, ATR), patent settlement announcement from March 4, 2026, and pipeline development data including RSV vaccine Phase 3 efficacy results.
Summary

Moderna, Inc. (MRNA) trading strategy overview with target price of $70.00 (21.1% upside from current $57.80), stop-loss price of $49.50, confidence level of 0.75, and risk score of 0.65 due to biotech volatility and negative earnings.

Operation strategy
  • Investment recommendation: BUY
  • Target price: $70.00 (21.1% upside from current $57.80)
  • Stop-loss: $49.50 (below 20-day MA and recent support)
  • Investment horizon: 3-6 months for RSV approval catalysts and pipeline developments
  • High volatility (ATR 4.74) requires careful position sizing
  • Stock broke through key resistance at $55.20 (January high)
  • All moving averages bullish (MA5 > MA10 > MA20 > MA60)
  • RSI overbought (72.57) suggests near-term consolidation likely

Core Support

Reasoning summary
  • Fundamental catalyst: $2.25 billion patent settlement with Arbutus/Genevant removes existential legal threat and provides operational certainty
  • Market's +16% reaction confirms settlement as net positive
  • Current negative P/E (-5.88) reflects transition period from COVID revenue to new products
  • Price/Sales ratio (10.42) reflects market optimism for pipeline commercialization
  • Strong balance sheet supports development: Current ratio 3.92, minimal debt (23.11% debt/assets)
  • Target $70 based on probability-adjusted value of near-term catalysts including RSV vaccine with 83.7% efficacy in Phase 3
  • 15 potential product launches in coming years and COVID/Flu/RSV combination vaccines in development
  • 97.48% profit ratio creates psychological support near $51.25 average cost
  • High volume surge (22.3M shares) suggests institutional accumulation